Case Report
BibTex RIS Cite

Etanercept-Induced Thrombocytopenia In A Patient With Ankylosing Spondylitis

Year 2022, Volume: 2 Issue: 1, 28 - 29, 29.01.2022

Abstract

Tumor necrosis factor-alpha (TNF-α), which is produced by macrophages and activated T lymphocyte cells, plays a main role in inducing further stimulation of other inflammatory cells. Anti-TNF-α drugs are used for induction and preservation of remission in patients with Ankylosing spondylitis. Etanercept, which is one of the most used Anti-TNF-α drugs, has side effects such as cytopenia but isolated thrombocytopenia is an uncommon adverse event. We report the case of a 40-year-old man diagnosed with Ankylosing spondylitis who developed Etanercept-induced isolated thrombocytopenia.

References

  • Referans1. Khanna D, Mcmahon M, Furst DE. Safety Of Tumor Necrosis Factor alpha Antagonists Drug Saf 2004;27(5):307–24.
  • Referans2. Keystone E. Safety Of Biologic Therapies—An Update. J Rheumatol 2005;32:8–12.
  • Referans3. Cush JJ. Safety Of New Biologic Therapies İn Rheumatoid Arthritis. Bullet Rheum Dis 2003–04;52.
  • Referans4. Malgarini RB, Pimpinella G. Etanercept And Methotrexate İn Rheumatoid Arthritis. Lancet 2004; 363(9422):1733.
  • Referans5. Rheum Dis Clin North Am 2001;27:427–4
  • Referans6. Selby LA, Hess D, Shashidar H, De Villiers WJ, Selby LA. Crohn's Disease, İnfliximab And İdiopathic Thrombocytopenic Purpura.Inflamm Bowel Dis Sep 2004;10(5):698–700
  • Referans7. S. K. Pathare, C. Heycock, J. Hamılton Tnf Blocker-İnduced Thrombocytopenia Rheumatology 2006;45: 1313–1314.
  • Referans8. M.J. Casanova A,⁎, M. Chaparro A, C, S. Martínez B, I. Vicuña B, J.P. Gisbert A, C Severe Adalimumab-İnduced Thrombocytopenia İn A Patient ith Crohn's Disease Journal Of Crohn's And Colitis (2012) 6, 1034–1037
  • Referans9. Valderílio Feijó Azevedo1, Marília Barreto Gameiro Silva2, Débora Karine Marinello3, Felipe Dunin Dos Santos4, Guilherme Barreto Gameiro Silva4 Leukopenia And Thrombocytopenia İnduced By Etanercept: Two Case Reports And Literature Review Rev Bras Reumatol 2011;52(1):107-112).
Year 2022, Volume: 2 Issue: 1, 28 - 29, 29.01.2022

Abstract

References

  • Referans1. Khanna D, Mcmahon M, Furst DE. Safety Of Tumor Necrosis Factor alpha Antagonists Drug Saf 2004;27(5):307–24.
  • Referans2. Keystone E. Safety Of Biologic Therapies—An Update. J Rheumatol 2005;32:8–12.
  • Referans3. Cush JJ. Safety Of New Biologic Therapies İn Rheumatoid Arthritis. Bullet Rheum Dis 2003–04;52.
  • Referans4. Malgarini RB, Pimpinella G. Etanercept And Methotrexate İn Rheumatoid Arthritis. Lancet 2004; 363(9422):1733.
  • Referans5. Rheum Dis Clin North Am 2001;27:427–4
  • Referans6. Selby LA, Hess D, Shashidar H, De Villiers WJ, Selby LA. Crohn's Disease, İnfliximab And İdiopathic Thrombocytopenic Purpura.Inflamm Bowel Dis Sep 2004;10(5):698–700
  • Referans7. S. K. Pathare, C. Heycock, J. Hamılton Tnf Blocker-İnduced Thrombocytopenia Rheumatology 2006;45: 1313–1314.
  • Referans8. M.J. Casanova A,⁎, M. Chaparro A, C, S. Martínez B, I. Vicuña B, J.P. Gisbert A, C Severe Adalimumab-İnduced Thrombocytopenia İn A Patient ith Crohn's Disease Journal Of Crohn's And Colitis (2012) 6, 1034–1037
  • Referans9. Valderílio Feijó Azevedo1, Marília Barreto Gameiro Silva2, Débora Karine Marinello3, Felipe Dunin Dos Santos4, Guilherme Barreto Gameiro Silva4 Leukopenia And Thrombocytopenia İnduced By Etanercept: Two Case Reports And Literature Review Rev Bras Reumatol 2011;52(1):107-112).
There are 9 citations in total.

Details

Primary Language English
Subjects ​Internal Diseases
Journal Section Case Reports
Authors

Attlla Önmez 0000-0002-7188-7388

Gulsah Altun 0000-0001-9596-6913

Türkay Akbaş 0000-0002-2150-6866

Birgül Öneç 0000-0003-2824-1044

Publication Date January 29, 2022
Submission Date December 30, 2021
Published in Issue Year 2022 Volume: 2 Issue: 1

Cite

EndNote Önmez A, Altun G, Akbaş T, Öneç B (January 1, 2022) Etanercept-Induced Thrombocytopenia In A Patient With Ankylosing Spondylitis. DAHUDER Medical Journal 2 1 28–29.



DAHUDER Medical Journal, hosted by Turkish JournalPark ACADEMIC, is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

by-nc-nd.png